PT 587 - Paul Austin - The Third Wave
In this episode, Joe Moore of Psychedelics Today sits down with Paul Austin, founder of The Third Wave, to dive deep into the evolution of microdosing and its growing role in psychedelic culture. Paul shares how his journey with microdosing LSD led him to launch The Third Wave in 2015 to make psychedelics more accessible through education. The conversation explores the latest research on microdosing, including clinical trials demonstrating its potential benefits for depression, mental clarity, and creativity. Paul and Joe discuss the nuances of different microdosing protocols, the role of psychedelics in performance optimization, and the impact of these substances on neuroplasticity. They also tackle key challenges, such as the lack of robust clinical research due to regulatory hurdles and the perceived risks associated with overuse. Beyond microdosing, they touch on the broader psychedelic landscape—regulatory shifts, emerging coaching models, and the future of psychedelic-assisted transformation. The discussion even ventures into intriguing intersections between psychedelics, AI, and the possibility of extraterrestrial intelligence. Tune in for a thought-provoking conversation on where microdosing fits into the larger psychedelic resurgence.
More description
In this episode, Joe Moore of Psychedelics Today sits down with Paul Austin, founder of The Third Wave, to dive deep into the evolution of microdosing and its growing role in psychedelic culture. Paul shares how his journey with microdosing LSD led him to launch The Third Wave in 2015 to make psychedelics more accessible through education. The conversation explores the latest research on microdosing, including clinical trials demonstrating its potential benefits for depression, mental clarity, and creativity. Paul and Joe discuss the nuances of different microdosing protocols, the role of psychedelics in performance optimization, and the impact of these substances on neuroplasticity. They also tackle key challenges, such as the lack of robust clinical research due to regulatory hurdles and the perceived risks associated with overuse. Beyond microdosing, they touch on the broader psychedelic landscape—regulatory shifts, emerging coaching models, and the future of psychedelic-assisted transformation. The discussion even ventures into intriguing intersections between psychedelics, AI, and the possibility of extraterrestrial intelligence. Tune in for a thought-provoking conversation on where microdosing fits into the larger psychedelic resurgence.
2025-02-25
71 min
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.
No generated results are available for this episode yet.
Transcript
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in
Chapters
No chapters available.